Glenview Capital Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $314M | Buy |
627,240
+376,715
| +150% | +$181M | 5.73% | 4 |
|
|
2026
Q1 | $123M | Buy |
250,525
+26,578
| +12% | +$14.4M | 3.09% | 9 |
|
|
2025
Q4 | $130M | Sell |
223,947
-58,994
| -21% | -$33.4M | 2.64% | 9 |
|
|
2025
Q3 | $137M | Buy |
282,941
+182,941
| +183% | +$85.2M | 3.05% | 8 |
|
|
2025
Q2 | $40.5M | Buy |
+100,000
| New | +$41.8M | 1.14% | 21 |
|
|
2020
Q3 | – | Sell |
-81,555
| Closed | -$29.6M | – | 50 |
|
|
2020
Q2 | $29.6M | Buy |
+81,555
| New | +$27.3M | 0.81% | 30 |
|
|
2020
Q1 | – | Sell |
-208,112
| Closed | -$67.6M | – | 53 |
|
|
2019
Q4 | $67.6M | Sell |
208,112
-261,404
| -56% | -$79.3M | 0.59% | 38 |
|
|
2019
Q3 | $137M | Sell |
469,516
-81,048
| -15% | -$23.2M | 1.44% | 22 |
|
|
2019
Q2 | $162M | Sell |
550,564
-430,025
| -44% | -$118M | 1.47% | 25 |
|
|
2019
Q1 | $268M | Sell |
980,589
-196,252
| -17% | -$48.8M | 2.4% | 17 |
|
|
2018
Q4 | $263M | Sell |
1,176,841
-1,033,101
| -47% | -$242M | 2.55% | 14 |
|
|
2018
Q3 | $539M | Sell |
2,209,942
-336,659
| -13% | -$77.4M | 3.43% | 8 |
|
|
2018
Q2 | $528M | Sell |
2,546,601
-416,142
| -14% | -$88.3M | 3.6% | 11 |
|
|
2018
Q1 | $612M | Sell |
2,962,743
-364,833
| -11% | -$76.6M | 3.58% | 8 |
|
|
2017
Q4 | $632M | Buy |
3,327,576
+598,749
| +22% | +$115M | 3.42% | 9 |
|
|
2017
Q3 | $516M | Sell |
2,728,827
-31,138
| -1% | -$5.64M | 3% | 12 |
|
|
2017
Q2 | $482M | Sell |
2,759,965
-212,095
| -7% | -$35.6M | 3.12% | 12 |
|
|
2017
Q1 | $457M | Sell |
2,972,060
-687,674
| -19% | -$105M | 3.03% | 13 |
|
|
2016
Q4 | $516M | Buy |
3,659,734
+973,418
| +36% | +$144M | 3.49% | 12 |
|
|
2016
Q3 | $427M | Sell |
2,686,316
-171,924
| -6% | -$26.5M | 3.06% | 10 |
|
|
2016
Q2 | $422M | Sell |
2,858,240
-752,312
| -21% | -$111M | 2.99% | 12 |
|
|
2016
Q1 | $511M | Sell |
3,610,552
-2,322,779
| -39% | -$311M | 3.74% | 10 |
|
|
2015
Q4 | $842M | Sell |
5,933,331
-2,577,873
| -30% | -$344M | 4.74% | 5 |
|
|
2015
Q3 | $1.04B | Sell |
8,511,204
-748,506
| -8% | -$97.5M | 5.16% | 3 |
|
|
2015
Q2 | $1.2B | Buy |
9,259,710
+2,348,939
| +34% | +$306M | 4.76% | 2 |
|
|
2015
Q1 | $928M | Sell |
6,910,771
-4,476,494
| -39% | -$577M | 4.24% | 3 |
|
|
2014
Q4 | $1.43B | Buy |
11,387,265
+11,598
| +0.1% | +$1.41M | 7.14% | 1 |
|
|
2014
Q3 | $1.38B | Buy |
11,375,667
+433,474
| +4% | +$52.7M | 7.24% | 1 |
|
|
2014
Q2 | $1.29B | Buy |
10,942,193
+1,381,300
| +14% | +$163M | 7.48% | 1 |
|
|
2014
Q1 | $1.15B | Buy |
9,560,893
+1,025,800
| +12% | +$122M | 7.53% | 1 |
|
|
2013
Q4 | $950M | Buy |
8,535,093
+451,432
| +6% | +$44.9M | 6.81% | 1 |
|
|
2013
Q3 | $745M | Sell |
8,083,661
-425,000
| -5% | -$38.4M | 6.28% | 1 |
|
|
2013
Q2 | $720M | Buy |
+8,508,661
| New | +$708M | 6.59% | 2 |
|
Other funds holding TMO
Glenview Capital Management's TMO Position: Q2 2026 in Review
Glenview Capital Management increased its Thermo Fisher Scientific (TMO) stake by 150% in Q2 2026, buying an estimated $181M and bringing the position to 627,240 shares worth $314M. The position accounts for 5.73% of the portfolio, ranked #4.
Glenview Capital Management first reported a position in TMO in Q2 2013 and has held it in 33 quarters since. The position peaked at $1.43B in Q4 2014. 2,617 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Glenview Capital Management held 627,240 shares of Thermo Fisher Scientific worth $314M as of Q2 2026.
- Glenview Capital Management bought 376,715 Thermo Fisher Scientific shares in Q2 2026, an estimated $181M.
- Thermo Fisher Scientific made up 5.73% of Glenview Capital Management's portfolio in Q2 2026, its #4 holding.
- Glenview Capital Management first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 33 quarters since.
- Glenview Capital Management's Thermo Fisher Scientific position peaked at $1.43B in Q4 2014.
- 2,617 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Glenview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.